Immutep Limited ((ASX: IMM, NASDAQ:IMMP) (“Immutep” or
“the Company”), a biotechnology company developing novel LAG-3 related immunotherapy treatments
for cancer and autoimmune disease, announces the first five patients have been treated in the INSIGHT-
003 study.
No additional safety signals have been observed in the study which is the first time a triple combination
therapy consisting of eftilagimod alpha (“efti”) and an existing approved standard of care combination of
chemotherapy (carboplatin) and an anti-PD-1 therapy has been administered.
Lead investigator, Prof. Dr. Salah-Eddin Al-Batran of the Institute of Clinical Cancer Research IKF said:
“The INSIGHT-003 study has commenced well. We are very pleased with the safety of the triple
combination so far and all patients are still participating in the study. This is important as it is the first time
patients have received a triple combination therapy with efti. Patient recruitment is advancing in line with
our projections.”
INSIGHT-003 is evaluating a triple combination therapy consisting of efti in conjunction with an existing
approved standard of care combination of chemotherapy and anti-PD-1 therapy. The study will continue
to recruit up to 20 patients with various solid tumours and additional results are expected in calendar year
2022.
